Kombivir

Combivir: Antiviral medicine for the treatment of HIV infection

Combivir is an antiviral medicine developed by Glaxo Operations UK and manufactured in the UK. It belongs to the pharmacological group of antiviral anti-HIV drugs and is a combination of two active components: lamivudine and zidovudine. Combivir is presented in the form of film-coated tablets.

Combivir is widely used to treat HIV infection in adults and children over 12 years of age who have progressive immunodeficiency. HIV infection is a serious public health problem, and Combivir plays an important role in reducing the replication of the human immunodeficiency virus (HIV) in the body, preventing the development of the disease and improving the quality of life of patients.

However, before using Combivir, some contraindications must be taken into account. It is not recommended for hypersensitivity to the components of the drug, severe neutropenia or anemia, as well as in children under 12 years of age, during breastfeeding and in the first trimester of pregnancy. However, in the second and third trimesters of pregnancy, the drug can be used if the expected benefit to the mother outweighs the potential risk to the fetus.

Like any medicine, Combivir may cause some side effects. These may include neutropenia, anemia, thrombocytopenia, redistribution of adipose tissue, headache, paresthesia, nausea, vomiting, diarrhea, increased levels of liver enzymes and others. Therefore, it is important to consult your doctor and strictly follow the instructions for use of this drug.

Combivir is one of the important drugs in the treatment of HIV infection. It helps patients reduce the viral load in the body, improve the immune system and prolong their life expectancy. However, to achieve the best results and minimize risks, it is necessary to use Combivir under the supervision of a physician and follow the recommendations for its use and possible side effects.